Efficacy and safety of RS plus bevacizumab versus RS plus fruquintinib as the third‐line therapy in patients with refractory metastatic colorectal cancer: A real‐world propensity score matching study
Journal of Evidence-Based Medicine · 2024
DOI: 10.1111/jebm.12652 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Evidence-Based Medicine, 2024. Verfasst von Yuwen Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Colorectal Cancer Center, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Bevacizumab, Propensity Score, Quinazolines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: The Department of Science and Technology of Sichuan Province, The Postdoctor Research Fund of West China Hospital, Sichuan University, The Nation-Sponsored Postdoctor Researcher Program.
Abstract (Originalsprache)
Background
This study aims to compare the effectiveness and safety of the combination of raltitrexed, S‐1 (RS), and fruquintinib with the combination of RS and bevacizumab in patients with refractory metastatic colorectal cancer (mCRC).
Methods
This retrospective cohort included mCRC patients who received the RS plus fruquintinib or regorafenib as the third‐line therapy from May 2019 to April 2023. A propensity score matching (PSM) analysis was used to balance the baseline characteristics of all patients. Overall survival (OS), progression‐free survival (PFS), tumor response, and safety of the two regimens were evaluated.
Results
Of the 153 patients enrolled, 123 patients received the RS plus bevacizumab and 30 patients received the RS plus fruquintinib. After PSM, 30 pairs were analyzed. Patients treated with RS plus fruquintinib had a longer PFS than those treated with RS plus bevacizumab before PSM (5.0 months vs. 4.3 months, p = 0.008) and after PSM (5.0 months vs. 4.4 months, p = 0.012). A longer OS was also observed in RS plus fruquintinib group before PSM and after PSM, but there was no statistic difference between two groups after PSM. Both objective response rate and disease control rate were higher in the RS plus fruquintinib cohort than those in the RS plus bevacizumab cohort before PSM, and the difference in values between the two groups reduced after PSM. The adverse effects (AEs) of both groups were well tolerated.
Conclusion
In patients with refractory mCRC, RS plus fruquintinib demonstrated a superior OS, PFS than RS plus bevacizumab and had manageable AEs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Colorectal Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
- West China Medical Publishers, West China Hospital of Sichuan University, Chengdu, China.
- Department of Biotherapy, Cancer Center, West China Hospital of Sichuan University, Chengdu, China.
- Department of Abdominal Oncology, Cancer Center, West China Hospital of Sichuan University, Chengdu, China.
ORCID-Profile: Meng Qiu
Förderung
- The Department of Science and Technology of Sichuan Province
- The Postdoctor Research Fund of West China Hospital, Sichuan University
- The Nation-Sponsored Postdoctor Researcher Program
- The 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University
Zitieren
APA
Zhou, Y., Xu, Q., Wang, J., Leng, W. B., Cao, P., Chen, Y., Luo, D. Y., Qiu, M., & Liu, J. (2024). Efficacy and safety of RS plus bevacizumab versus RS plus fruquintinib as the third‐line therapy in patients with refractory metastatic colorectal cancer: A real‐world propensity score matching study. Journal of Evidence-Based Medicine. https://doi.org/10.1111/jebm.12652
Vancouver
Zhou Y, Xu Q, Wang J, Leng WB, Cao P, Chen Y, et al. Efficacy and safety of RS plus bevacizumab versus RS plus fruquintinib as the third‐line therapy in patients with refractory metastatic colorectal cancer: A real‐world propensity score matching study. Journal of Evidence-Based Medicine. 2024. doi:10.1111/jebm.12652
BibTeX
@article{Zhou2024,
author = {Zhou, Yuwen and Xu, Qian and Wang, Jialing and Leng, Wei-Bing and Cao, Peng and Chen, Ye and Luo, De-Yun and Qiu, Meng and Liu, Jiyan},
title = {Efficacy and safety of RS plus bevacizumab versus RS plus fruquintinib as the third‐line therapy in patients with refractory metastatic colorectal cancer: A real‐world propensity score matching study},
journal = {Journal of Evidence-Based Medicine},
year = {2024},
doi = {10.1111/jebm.12652}
}
EUVIMED